Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Sponsor

Respirent Pharmaceuticals Co Ltd. (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT05085587

Collaborator

Becro Ltd. (Industry)

Enrollment

Location

Arms

Anticipated Duration (Months)

6.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder

Condition or Disease	Intervention/Treatment	Phase
Bioequivalence Asthma	Drug: Test Drug: Reference	Phase 1

Detailed Description

A bioequivalence study of a single dose of the fixed-dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder administered from Fluticasone propionate 250 mcg and Salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals (test-Τ) as 2 inhalations and ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK (reference-R) in healthy volunteers under fasting conditions. The study will be one-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory blinded

Study Design

Study Type:

Interventional

Anticipated Enrollment :

18 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Intervention Model Description:

One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded studyOne-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study

Masking:

Single (Outcomes Assessor)

Masking Description:

Laboratory blinded

Primary Purpose:

Other

Official Title:

A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Bioequivalence Study With Pharmacokinetic Endpoints Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Actual Study Start Date :

Oct 1, 2021

Anticipated Primary Completion Date :

Oct 25, 2021

Anticipated Study Completion Date :

Dec 30, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Test Product Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals	Drug: Test 2 inhalations of Test and Reference product in each study period Other Names: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
Active Comparator: Reference Product ADVAIR DISKUS 250/50	Drug: Reference 2 inhalations of Test and Reference product in each study period Other Names: ADVAIR DISKUS 250/50

Arm

Intervention/Treatment

Experimental: Test Product

Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals

Drug: Test

2 inhalations of Test and Reference product in each study period

Other Names:

Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals

Active Comparator: Reference Product

ADVAIR DISKUS 250/50

Drug: Reference

2 inhalations of Test and Reference product in each study period

Other Names:

ADVAIR DISKUS 250/50

Outcome Measures

Primary Outcome Measures

Cmax for Fluticasone Propionate (FP) [3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration]]
Maximum plasma concentration, it is read directly from the raw data
Cmax for Salmeterol [Time Frame: 3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration]]
Maximum plasma concentration, it is read directly from the raw data
AUC(0-t) for Fluticasone Propionste (FP) [Time Frame: 3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration]]
Area under the plasma concentration curve from time 0 to the last measured concentration at time t
AUC(0-t) for Salmeterol [Time Frame: 3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration]]
Area under the plasma concentration curve from time 0 to the last measured concentration at time t

Secondary Outcome Measures

AUC0-∞ [up to 36 hours post-administration]
Area under the plasma concentration-time curve extrapolated to infinity AUC0-∞=AUC0-t+Ct/λz. Ct is the last measured concentration and λz is the apparent terminal elimination rate constant
Tmax [up to 36 hours post-administration]
Time until Cmax is reached, it is read directly from the observed concentrations
t1/2 [up to 36 hours post-administration]
Plasma concentration halflife, it is calculated from the ratio 0.693/λZ
λz [up to 36 hours post-administration]
Terminal elimination rate constant, calculated from the slope of the final phase of the ln-concentration curve versus time with regression analysis
Residual Area [up to 36 hours post-administration]
[AUC(0-∞)-AUC(0-t)]/AUC(0-∞)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Healthy volunteers of both genders, aged ≥18 and ≤55 years.
Subjects with Body Mass Index (ΒΜΙ) ≥18.5 and <30.0 kg/m2.
Healthy volunteers are declared healthy based on medical history, physical examination, ECG, pulmonary function test (a forced expiratory volume in 1 second (FEV1) >=90% of the predicted normal value), and clinical laboratory values within the laboratory stated normal range; if not within this range, they must be without any clinical significance according to the Investigator.
Females who participate in the study are either at reproductive age i.e.pre-menopausal or unable to gestate [i.e. post-menopausal (absence of menses for 12 months prior to drug administration), hysterectomy, bilateral oophorectomy, tubal ligation at least 6 months prior to drug administration].
Subjects that are non-smokers.
Subjects that, in the opinion of the principal investigator/medical officer, are able to communicate and comply with the study procedures and protocol restrictions as evidenced by the Informed Consent Form (ICF) duly read, signed and dated by the subject prior to study initiation.
Subjects able to use the inhalers according to given instructions, as judged by the Investigator or study nurse.

Exclusion Criteria:

Hypersensitivity to the active substance(s) or to the excipient (lactose which contains small amounts of milk protein may cause allergic reactions) or related class (any sympathomimetic drug or any inhaled, intranasal, or systemic corticosteroid therapy) of the medicinal product
Clinically significant illness or surgery within 12 weeks prior to dosing.
Clinically significant ECG abnormalities or vital sign abnormalities (seated systolic blood pressure <90 or >140 mmHg, seated diastolic blood pressure <50 or >90 mmHg or heart rate less than 50 or over 100 bpm) at screening.
Clinically significant history or presence of chronic bronchitis, emphysema,asthma or any other lung disease.
History or presence of pulmonary tuberculosis.
Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 12 weeks prior to the screening visit.
History or presence of significant cardiovascular, endocrinal, neurologic, immunological, psychiatric or metabolic disease.
History of significant alcohol or drug abuse within one year prior to the screening visit.
Regular use of alcohol within six months prior to screening visit (more than 14 alcohol units per week) [1Unit =150 ml of wine, 360 ml of beer, or 45 ml of 40% alcohol].
Inability to abstain from alcohol for the duration of study period.
Presence of disease markers for Hepatitis B, Hepatitis C or HIV at screening.
Positive results for drugs of abuse (barbiturates, marijuana, opioids, benzodiazepines and methadone) in saliva before each administration.
Positive alcohol breath test before each administration.
Use of soft drugs (such as marijuana) within three months prior to screening or hard drugs such as crack, cocaine or heroin within one year prior to screening visit
Intake of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers are barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin; examples of inhibitors are, erythromycin, ketoconazole, indinavir, cobicistat-containing products) within one month prior to administration of the study medication. Under these circumstances, subject inclusion will be judged by the principal investigator.
History of peptic ulcer, other gastrointestinal disorders (e.g. chronic diarrhoea, irritable bowel syndrome) or unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting) or significant hepatic, renal or other condition that is known to interfere with the absorption, distribution, metabolism or excretion of the drug.
Use of oral or parenteral corticosteroids in the previous twelve (12) weeks
Eye disorders especially Glaucoma (or a family history of glaucoma)
Use of prescription medication (within 14 days prior to the first administration of study medication) or over-the-counter (OTC) products (including food supplements vitamins and herbal supplements) within one week (7 days) prior to the first administration of study medication, except for topical products without systematic absorption. Contraceptives are allowed.
Vaccination for prophylaxis from seasonal flu or any other vaccination within seven days prior to administration
History of allergy to any food, intolerance or special diet, that in the opinion of the medical sub-investigator could contraindicate the subject's participation in the study.
A depot injection or an implant of any drug (except hormonal contraceptives) within 3 months prior to treatment administration.
Donation of plasma (500 ml) within 7 days prior to treatment administration.
Donation of whole blood or loss of whole blood ≥ 500 ml prior to administration of the study medication within 30 days prior to treatment administration.
Participation in another clinical trial simultaneously.
Subjects receiving special diet or having intolerance in any of the provided study meals or refusing to eat the study meals
Application of tattoo or body piercing within 30 days prior to treatment administration.
Non-tolerance to venipuncture.
Breastfeeding women.
Positive pregnancy test at screening
Females of reproductive age that had sexual intercourse with a non-sterile male partner without protection within 14 days prior to drug administration

Reliable contraception methods are considered the following:

combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal or transdermal
progestogen-only hormonal contraception associated with inhibition of ovulation oral, implanable or injectable
intrauterine device (IUD)
intrauterine hormone-releasing system (IUS)
bilateral tubal occlusion
vasectomised partner
sexual abstinence